Clinical Effectiveness and Safety of Oral Semaglutide in a Real-World Cohort of Patients with Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes and Obesity: A Propensity Score-Matched Analysis

<b>Bacground/Objectives</b>: There is limited evidence on the role of glucagon-like peptide-1 receptor agonists in heart failure. We aimed to analyze the clinical efficacy of oral semaglutide in terms of health status and change in body weight in patients with heart failure with reduced...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Alicia Trenas-Calero, Nuria Prieto-Laín, Miguel A. Pérez-Velasco, Claudia Padilla-Leiva, José M. Pérez-Ruiz, Fátima I. Ruíz-Rodríguez, Ricardo Gómez-Huelgas, María-Rosa Bernal-López, Luis M. Pérez-Belmonte
Format:	Article
Language:	English
Published:	MDPI AG 2026-06-01
Subjects:	semaglutide heart failure reduced left ventricular ejection fraction type 2 diabetes obesity
Online Access:	https://www.mdpi.com/1424-8247/19/6/894